Cargando…
Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer
Circulating tumor DNA (ctDNA) isolated from plasma has great potential in identification of gene mutation in non-small cell lung cancers (NSCLC), which is a non-invasive technique and can avoid the inherent shortcomings of tissue biopsy. However the ability of NGS to detect gene mutation in plasma c...
Autores principales: | Yao, Yu, Liu, Jinghao, Li, Lei, Yuan, Yuan, Nan, Kejun, Wu, Xin, Zhang, Zhenyu, Wu, Yi, Li, Xin, Zhu, Jiaqi, Meng, Xuehong, Wei, Longgang, Chen, Jun, Jiang, Zhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356786/ https://www.ncbi.nlm.nih.gov/pubmed/27791985 http://dx.doi.org/10.18632/oncotarget.12883 |
Ejemplares similares
-
CNV Detection from Circulating Tumor DNA in Late Stage Non-Small Cell Lung Cancer Patients
por: Peng, Hao, et al.
Publicado: (2019) -
Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients
por: Yue, Dongsheng, et al.
Publicado: (2022) -
Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non‐small cell lung cancer
por: Cheng, Lei, et al.
Publicado: (2023) -
Prediction of the Therapeutic Effects of Pembrolizumab and Nivolumab in Advanced Non-Small Cell Lung Cancer by Platelet-Derived Microparticles in Circulating Blood
por: Liu, Tingting, et al.
Publicado: (2021) -
Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer
por: Yuan, Shuai, et al.
Publicado: (2020)